Tests for follicular lymphoma: choosing a biopsy, establishing stage and preparing safely for treatment

An enlarged neck node or a scan describing several swollen lymph nodes does not establish follicular lymphoma. Infection, immune conditions and other cancers can produce overlapping findings. A useful investigation sequence identifies the tissue diagnosis, maps the distribution of disease and checks whether lymphoma is affecting organs or blood-cell production. The purpose is to answer clinical questions, not to complete the largest possible package of tests.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Record when the swelling was first noticed, which areas have changed and whether a node has previously become smaller without treatment. Mention recent infections, dental problems and vaccination, since these can affect lymph nodes or imaging. Describe fever with measured temperatures, weight change with dates and starting weight, and night sweats in terms of whether clothes or bedding become soaked. These details are more useful than an undated list of general symptoms.
PET/CT combines metabolic information with anatomical images. It can help establish whether lymphoma is localized or present in several regions, and is particularly useful when apparently limited disease might be treated with radiation. A metabolically active focus may also be inflammation or infection. Recent procedures and treatments can affect interpretation, so provide those dates and follow the center's preparation instructions, including advice relevant to diabetes.
Prepare an inventory of slides or blocks that can be borrowed, the complete stain and FISH reports, all original imaging and dated blood results. Identify the institution and sampling site for each specimen and whether it was obtained before or after treatment. Keep original-language documents alongside translations. “Negative,” “not detected” and “not tested” describe different situations and should not be merged in a translated summary.

Quick answer

Full guide

If a biopsy has already been performed, start by obtaining the full report, including additional stains, molecular results and the sampling location. A receiving specialist may be able to request a review of the existing slides before recommending another procedure. A photograph of the final diagnosis line leaves out information that could prevent unnecessary testing. If no tissue has been obtained, a hematologist can help coordinate the choice of biopsy with a surgeon or interventional radiologist. NICE diagnostic recommendations

Give the clinician a timeline that can be interpreted

Record when the swelling was first noticed, which areas have changed and whether a node has previously become smaller without treatment. Mention recent infections, dental problems and vaccination, since these can affect lymph nodes or imaging. Describe fever with measured temperatures, weight change with dates and starting weight, and night sweats in terms of whether clothes or bedding become soaked. These details are more useful than an undated list of general symptoms.

The assessment also reviews previous cancer treatment, autoimmune disease, hepatitis and other infection history, current medicines and supplements. Examination checks accessible nodes, the liver and spleen and any signs of organ pressure. A patient who takes anticoagulants or antiplatelet medication must tell the biopsy team; the clinician should decide how to manage the medicine around the procedure. Stopping a prescription independently can create a different medical risk.

New weakness, significant breathlessness or severe abdominal pain can change the order of investigations. A threatened airway or other acute complication needs prompt local assessment even while a lymphoma diagnosis is being established. A stable patient can usually focus on obtaining the most informative tissue sample and avoiding repeated incomplete procedures.

Obtain enough tissue to examine the pattern

When a node is accessible and operative risk is acceptable, an excision biopsy often allows the pathologist to study the follicular architecture and identify areas containing larger cells. A core-needle biopsy can be appropriate for deeper disease or when an operation would be disproportionately risky. The choice depends on access, safety, expected tissue yield and the information required. A more extensive operation is not automatically a better diagnostic procedure.

Fine-needle aspiration can provide cells for certain investigations, including flow cytometry in appropriate circumstances. It may not provide enough architecture for a complete diagnosis or grading assessment. A report saying that lymphoma is suspected and a tissue biopsy is recommended should be treated as an unfinished diagnostic step. Accepting an insufficient sample solely to avoid another appointment may delay a reliable treatment decision.

Tell the sampling team that lymphoma is suspected before the procedure. Some studies need material handled differently from routine formalin-fixed tissue. Coordination helps the laboratory allocate samples for morphology, flow cytometry and selected genetic tests. If another biopsy is needed, the site should be representative as well as safe. A newly fast-growing mass may be more informative than the easiest old node to reach. NCI pathology and treatment reference

Understand why the laboratory uses several markers

The pathologist interprets the structure and cells together with an appropriate stain panel. B-cell markers such as CD20, germinal-center markers such as CD10 and BCL6, BCL2 and other selected findings help distinguish follicular lymphoma from reactive tissue and other lymphomas. Ki-67 describes proliferative activity in the sampled tissue. One percentage should not independently determine that transformation has occurred or that a particular chemotherapy intensity is required.

FISH or another genetic method may investigate rearrangements such as those involving BCL2. A change common in classic follicular lymphoma is not present in every case, and a positive result still needs its tissue context. Broad sequencing is not a replacement for good morphology and an appropriate immunohistochemical panel. Ask which diagnostic uncertainty or treatment decision a proposed molecular test is expected to resolve.

The full disease name matters when the report describes grade 3A, legacy grade 3B, pediatric-type disease or a duodenal-type pattern. A young adult does not automatically have pediatric-type follicular lymphoma, and finding disease in the duodenum does not by itself establish the distinct duodenal-type entity. The specialist must reconcile the pathology with age, distribution and clinical behavior. ESMO diagnostic guideline

Blood tests serve more than one purpose

A complete blood count can identify anemia, reduced neutrophils or low platelets. Potential causes include marrow involvement, effects of an enlarged spleen, infection, nutritional problems and medicines. Trends can be more informative than a single result. Kidney and liver function, albumin and lactate dehydrogenase help assess the clinical situation, but an elevated LDH is not specific for lymphoma and cannot substitute for tissue diagnosis.

Before anti-CD20 therapy or another substantially immunosuppressive treatment, the team generally evaluates hepatitis B status and follows up relevant positive results. Hepatitis C, HIV and other infection tests are chosen according to the regimen and risk. Someone who was told years ago that hepatitis B had “cleared” should still provide the original results if possible. Previous infection may remain relevant because immune suppression can permit reactivation.

Additional baseline studies should match the planned treatment. An electrocardiogram and echocardiogram may be needed before a potentially cardiotoxic regimen. Pregnancy assessment, fertility counseling and evaluation of immune function may also change the plan. The clinician should explain the connection between each investigation and a foreseeable treatment risk, rather than presenting all tests as mandatory for every patient. NCI patient guide

PET/CT maps disease but does not replace a biopsy

PET/CT combines metabolic information with anatomical images. It can help establish whether lymphoma is localized or present in several regions, and is particularly useful when apparently limited disease might be treated with radiation. A metabolically active focus may also be inflammation or infection. Recent procedures and treatments can affect interpretation, so provide those dates and follow the center's preparation instructions, including advice relevant to diabetes.

Before repeating a scan at another hospital, send the original DICOM files for review. The radiologist needs the image series, acquisition details and full scanned area, not just selected screenshots. A recent technically adequate scan may answer the question already; an old or incomplete study may not. A meaningful comparison must identify the same lesions rather than assume that two similarly described nodes are identical.

A particularly active lesion can raise concern for transformation and help guide a biopsy. There is no universal SUV number that conclusively diagnoses transformation in every patient. A high reading should lead to a tissue-based assessment when the answer would alter management. Likewise, slow behavior elsewhere does not rule out a clinically different process in one rapidly changing site. German guideline on diagnosis and follow-up

Decide what a bone marrow examination would add

Keep a usable baseline description of affected regions, measurable lesions and the imaging date. Frameworks such as Lugano help teams describe stage and response consistently, although a recommendation for one lymphoma subtype should not be automatically applied to another. Lugano evaluation consensus

Marrow sampling may establish involvement by lymphoma or help explain low blood counts. It can be useful when confirmation of a localized stage would affect treatment, when blood abnormalities remain unexplained or when the result would alter another decision. PET and marrow examination have different limitations. The team should explain why a biopsy adds information in the particular case rather than stating that every PET scan permanently eliminates any need for marrow sampling.

Ask what will be collected and how discomfort will be controlled. An aspirate and a trephine biopsy do not provide identical information. Low platelets, anticoagulation and a previous serious reaction to local anesthetic should be discussed in advance. Instructions for pressure on the site, dressing care and unexpected bleeding belong in the discharge advice. The marrow findings must then be interpreted alongside the lymph-node pathology and blood results.

Turn the completed workup into an actionable conclusion

At the results appointment, the patient should receive the complete diagnostic name, disease stage, clinically important sites and a clear statement about whether treatment is currently indicated. Unresolved findings should be listed with the next test or review that will address them. A stack of reports without an integrated explanation can leave the patient less certain despite having completed extensive testing.

FLIPI uses clinical factors, including age, stage, hemoglobin, LDH and nodal areas, to support a prognostic discussion. It does not convert a stable asymptomatic case into an automatic treatment emergency. Similarly, research on progression within 24 months identifies an adverse clinical course in groups after therapy; the initial workup cannot tell an individual with certainty that early progression will occur. POD24 validation across clinical trials

If monitoring is chosen, establish the next appointment and the symptoms that should bring it forward. If radiation is planned, make the pre-biopsy images available to the radiation oncologist. If systemic treatment is planned, ensure that infection prevention and relevant organ assessments are completed before the first dose. These links between results and action are what make an investigation useful.

Arrange a diagnostic review in China without assuming every test must be repeated

Prepare an inventory of slides or blocks that can be borrowed, the complete stain and FISH reports, all original imaging and dated blood results. Identify the institution and sampling site for each specimen and whether it was obtained before or after treatment. Keep original-language documents alongside translations. “Negative,” “not detected” and “not tested” describe different situations and should not be merged in a translated summary.

Ask the China center to specify which existing studies it can use and which need repetition because of inadequate material, age of the test or a clinical change. An itemized RMB quotation should distinguish the biopsy procedure, anesthesia, pathology review, extra stains, imaging, marrow examination and external laboratory charges. This article has no verified hospital quotation, so it cannot supply a defensible universal price. Chinese domestic insurance charges are not the same as an international self-pay estimate.

Specimen transport, routine processing and additional testing have different turnaround times. Obtain estimated reporting dates from the actual laboratory and leave room for a further investigation before booking an inflexible return flight. A clinically stable patient may be able to complete the initial record review remotely. Persistent high fever, substantial bleeding, confusion or breathing difficulty should instead trigger local urgent assessment. The diagnostic timetable should follow the medical question and the patient's condition. NICE follicular lymphoma pathway